| pubmed-article:12890205 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12890205 | lifeskim:mentions | umls-concept:C0031740 | lld:lifeskim |
| pubmed-article:12890205 | lifeskim:mentions | umls-concept:C0002563 | lld:lifeskim |
| pubmed-article:12890205 | lifeskim:mentions | umls-concept:C1527358 | lld:lifeskim |
| pubmed-article:12890205 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:12890205 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:12890205 | lifeskim:mentions | umls-concept:C0022086 | lld:lifeskim |
| pubmed-article:12890205 | lifeskim:mentions | umls-concept:C0332237 | lld:lifeskim |
| pubmed-article:12890205 | lifeskim:mentions | umls-concept:C1522168 | lld:lifeskim |
| pubmed-article:12890205 | lifeskim:mentions | umls-concept:C0072497 | lld:lifeskim |
| pubmed-article:12890205 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12890205 | pubmed:dateCreated | 2003-7-31 | lld:pubmed |
| pubmed-article:12890205 | pubmed:abstractText | In 5-aminolaevulinic acid (ALA)-photodynamic therapy (PDT), the prodrug ALA is endogenously converted to the active sensitizer protoporphyrin IX (PpIX), while further conversion of PpIX to haem requires iron. | lld:pubmed |
| pubmed-article:12890205 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12890205 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12890205 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12890205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12890205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12890205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12890205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12890205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12890205 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12890205 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12890205 | pubmed:issn | 0007-0963 | lld:pubmed |
| pubmed-article:12890205 | pubmed:author | pubmed-author:RhodesL ELE | lld:pubmed |
| pubmed-article:12890205 | pubmed:author | pubmed-author:FarrarWW | lld:pubmed |
| pubmed-article:12890205 | pubmed:author | pubmed-author:ChoudryKK | lld:pubmed |
| pubmed-article:12890205 | pubmed:author | pubmed-author:BrookeR C CRC | lld:pubmed |
| pubmed-article:12890205 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12890205 | pubmed:volume | 149 | lld:pubmed |
| pubmed-article:12890205 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12890205 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12890205 | pubmed:pagination | 124-30 | lld:pubmed |
| pubmed-article:12890205 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:meshHeading | pubmed-meshheading:12890205... | lld:pubmed |
| pubmed-article:12890205 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12890205 | pubmed:articleTitle | The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. | lld:pubmed |
| pubmed-article:12890205 | pubmed:affiliation | Photobiology Unit, Dermatology Centre, Hope Hospital, Salford, Manchester M6 8HD, U.K. | lld:pubmed |
| pubmed-article:12890205 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12890205 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12890205 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12890205 | lld:pubmed |
